TENOTEN

Tenoten has been studied primarily in Russian clinical trials, including double-blind placebo-controlled randomized studies in both adults and children. In adults, it demonstrated anxiolytic efficacy comparable to grandaxin and antidepressant effects comparable to amitriptyline and sertraline in patients with anxiety, depression, hypertension, and epilepsy. A multicenter placebo-controlled trial in 237 children showed statistically significant improvement in academic skills over 12 weeks with no serious adverse events. A separate trial in 184 infants with perinatal brain injury showed 77.5% responder rate versus placebo. However, nearly all evidence originates from Russian institutions and the manufacturer's research network, limiting independent verification. The ultra-low dose antibody mechanism lacks robust mechanistic validation in Western pharmacological literature.